×
Hytest, a specialist provider of high-quality raw materials for in vitro diagnostics, is pleased to announce the launch of its new recombinant neurofilament light chain (NfL) antigen, Cat. #8NF5.
The new antigen complements Hytest’s established portfolio of NfL antibodies (Cat. #4NF3), providing customers with an expanded reagent solution for the development and validation of NfL assays.
NfL is increasingly studied as a biomarker of neuro-axonal injury in neurological diseases and conditions, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), dementia, traumatic brain injury and stroke. As interest in blood-based neurological biomarkers continues to grow, well-characterized antigen reagents are important for the development of reliable and reproducible NfL assays.
Hytest’s NfL antigen is a full-length recombinant human NfL protein consisting of 543 amino acids and based on the native human NfL sequence listed in UniProt P07196.
Key Product Features of Cat. #8NF5
Hytest’s neuroscience portfolio provides a broad range of reagents for neurological biomarker assay development. In addition to anti-NfL antibodies and recombinant NfL antigen, the portfolio includes antibodies and antigens for other biomarkers associated with neuroinflammation and neurodegeneration, including GFAP antibodies and antigen (Cat. #4G25 and 8G47), beta-amyloid 1–42 antibodies (Cat. #4BA3), S100 antibodies (Cat. #4S37), and several S100 antigens. By bringing these reagents together, Hytest supports assay developers and diagnostic manufacturers throughout the neurological biomarker development process—from individual NfL assays to broader multi-marker panels—with reliable materials from one experienced supplier.
For details, please contact the Hytest Sales team.
Copyright © Hytest Ltd.